Crown Bioscience, a global drug discovery and development service company, has raised $26.55 million of Series D funding led by Lilly Asia Ventures (through its Lilly Asia Ventures Fund II). The company provides translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: oncology and metabolic diseases. Crown Bioscience has now raised over $77 million in funding to date. It will use the new capital to fund rapid expansion plans for its translational platform technologies, which allow drug development companies to make quicker and better-informed decisions on clinical drug candidates. Crown Bioscience will also use the investment to actively pursue potential acquisition opportunities.